| Title | Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block. | | Author(s) | Hogg RM, Mirakhur RK | | Institution | Department of Anaesthetics and ICM, Queen's University, Belfast, UK. | | Source | Expert Rev Neurother 2009 May; 9(5):599-608. | | Abstract | Neostigmine, the currently used agent for reversal of neuromuscular block, has several drawbacks, such as a slow onset of peak effect, inability to reverse deep block and the occurrence of widespread muscarinic effects. Sugammadex is a new class of reversal agent that acts by encapsulating the molecules of the relaxants rocuronium and vecuronium, for which it is a specific antagonist. Clinical trials in over 2000 subjects have shown it to be effective for reversal of block by these two relaxants even from deep levels, in doses of 2.0-4.0 mg/kg. Sugammadex can also reverse an intense (profound) high-dose rocuronium block, but the dose required in this situation is 16.0 mg/kg. The agent has been found to be safe so far, with few side effects. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19402771 |
|
